TIKRF - Tikcro Technologies Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1600
0.0000 (0.00%)
At close: 12:40PM EDT
Stock chart is not supported by your current browser
Previous Close0.1600
Open0.1600
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1600 - 0.1600
52 Week Range0.1600 - 0.4000
Volume75
Avg. Volume558
Market Cap1.581M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 4, 2019 - Mar 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswirelast month

    Tikcro Technologies Reports Fourth Quarter and Full Year 2018 Results

    NESS -ZIONA, Israel , April 12, 2019 /PRNewswire/ -- High Level Pre-Clinical Results Showed in AACR 2019 Annual Conference Tikcro Technologies Ltd. (OTCQB: TIKRF), a pre-clinical stage developer of antibodies ...

  • PR Newswire2 months ago

    Tikcro Technologies To Present Unique Properties of a Novel CTLA-4 Antibody at the AACR Annual Meeting 2019 in the U.S.

    REHOVOT, Israel , March 14, 2019 /PRNewswire/ -- Tikcro Technologies Ltd. (OTCQB: TIKRF), a pre-clinical stage antibody immunotherapy company leveraging a novel mimitope approach for antibody generation, ...

  • PR Newswire5 months ago

    Tikcro Technologies Announces 2018 Annual General Meeting

    TEL AVIV, Israel, Dec. 13, 2018 /PRNewswire/ --  Tikcro Technologies Ltd. (TIKRF), a pre-clinical stage developer of antibodies for cancer immune-therapy, today announced that its 2018 Annual General Meeting of Shareholders will be held on Sunday, January 20, 2019 at 11:00 a.m. (Israel time), at the Company's office located at 7 Sapir Street, Ness Ziona, Israel. To approve the consideration of audited financial statements for the year ended December 31, 2017.

  • PR Newswire6 months ago

    Tikcro Technologies Reports Third Quarter 2018 Results

    NESS -ZIONA, Israel , Nov. 14, 2018 /PRNewswire/ -- -- Continued Advancement of a New CTLA-4 Antibody with Superior Pre-clinical Qualities -- Tikcro Technologies Ltd. (OTCQB: TIKRF), a pre-clinical stage ...

  • PR Newswire8 months ago

    Tikcro Technologies Reports Second Quarter 2018 Results

    Continued Advancement of a New CTLA-4 Antibody with Superior Pre-clinical Qualities NESS -ZIONA, Israel , Sept. 17, 2018 /PRNewswire/ -- Tikcro Technologies Ltd. (OTCQB: TIKRF), a pre-clinical stage developer ...

  • PR Newswire11 months ago

    Tikcro Technologies Reports First Quarter 2018 Results

    NESS -ZIONA, Israel , June 6, 2018 /PRNewswire/ --   Continued Advancement of a New Full-Human CTLA-4 Antibody Tikcro Technologies Ltd. (OTCQB: TIKRF), a pre-clinical stage developer of antibodies for ...